Bioequivalence and Bioavailability Forum 19:58 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

ElMaestro
Hero

Denmark,
2018-04-15 14:50

Posting: # 18684
Views: 553
 

 Shenanigans [BE/BA News]

Hi all,

story from New York Times.

I have seen some cases of the same phenomenon in Europe, when wholesalers have been very forthcoming with supplies of trial material until they are told it is for use as a comparator in a BE trial. Then suddenly there is 'a problem with the supply chain' or some such vague excuse for quickly terminating the call.

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,783 posts in 4,003 threads, 1,259 registered users;
online 11 (0 registered, 11 guests [including 9 identified bots]).

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed